Capsida Biotherapeutics

Biotechnology ResearchCalifornia, United States11-50 Employees

Capsida Biotherapeutics is a biotechnology company focused on developing targeted, non-invasive gene therapies for debilitating and life-threatening genetic disorders. Its approach aims to deliver genetic payloads to specific cells and organs while limiting effects on non-target tissues, with intravenous administration enabling a non-invasive delivery route.

The company maintains a growing intellectual property portfolio, including more than 30 patent applications and one issued U.S. patent, and its research spans a range of life-threatening diseases, with an initial emphasis on neurologic conditions. Based in Newbury Park, California, Capsida has strategic collaborations with AbbVie and CRISPR that provide external validation of its platform, and its origins trace to work conducted in the laboratory of Viviana Gradinaru, Ph.D., at the California Institute of Technology. In 2026, leadership changes occurred, with the departures of the chief executive officer and the chief business officer.

Sign up for free to view info

Email Format Employee directory